SISRAM MED (01696): Shareholder restructuring at the holding level completed.

Ruix Medical Technology (01696) announced that at the level of the controlling shareholder, a proposal for reorganization was suggested. According to the reorganization announcement, Fosun Pharma's indirectly wholly-owned subsidiary Nengyue and Meizhong Huli have respectively signed agreements to transfer all of their company shareholding rights (accounting for approximately 71.42% of the total issued shares of the company as of the date of this announcement) to another Fosun Pharma indirectly wholly-owned subsidiary FPI. On April 22, 2026, the board of directors of the company received a notice from Fosun Pharma stating that, according to the terms of their agreement, this reorganization has been completed. As a result, as of the date of this announcement, Fosun Pharma's indirectly wholly-owned subsidiary FPI holds 3.345 billion shares of the company, and Fosun Pharma's indirect ownership of the company's equity remains unchanged.